Publicaciones en colaboración con investigadores/as de Tel Aviv University (65)

2024

  1. A new framework for the diagnosis, staging and management of obesity in adults

    Nature Medicine

  2. A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial

    Future oncology (London, England), Vol. 20, Núm. 13, pp. 799-809

  3. A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial

    Future Oncology, Vol. 20, Núm. 13, pp. 799-809

  4. Comparison of assays measuring extracellular vesicle tissue factor in plasma samples: communication from the ISTH SSC Subcommittee on Vascular Biology

    Journal of Thrombosis and Haemostasis

  5. Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial

    Gynecologic Oncology, Vol. 187, pp. 128-138

  6. Endoscopic GI placement of capsule endoscopy to investigate the small bowel: a multicenter European retrospective series of 630 procedures in adult patients

    Gastrointestinal Endoscopy, Vol. 100, Núm. 3, pp. 492-500

  7. Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial

    Gynecologic Oncology, Vol. 184, pp. 168-177

  8. Improving quality of life in the elderly: hearing loss treatment with cochlear implants

    BMC Geriatrics, Vol. 24, Núm. 1

  9. Technical considerations for isolated limb perfusion: A consensus paper

    European Journal of Surgical Oncology, Vol. 50, Núm. 6

  10. Thyroid hormones for euthyroid patients with simple goiter growing over time: a survey of European thyroid specialists

    Endocrine

  11. Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy

    European Journal of Cancer, Vol. 208

  12. Treatment of Obesity with Thyroid hormones in Europe. Data from the THESIS* Collaboration

    Journal of Endocrinological Investigation

  13. Use of levothyroxine for euthyroid, thyroid antibody positive women with infertility: Analyses of aggregate data from a survey of European thyroid specialists (Treatment of Hypothyroidism in Europe by Specialists: An International Survey)

    Clinical Endocrinology, Vol. 101, Núm. 2, pp. 180-190

2023

  1. Characteristics of specialists treating hypothyroid patients: the “THESIS” collaborative

    Frontiers in Endocrinology, Vol. 14

  2. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

    Blood, Vol. 141, Núm. 3, pp. 219-230

  3. Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study

    eClinicalMedicine, Vol. 63

  4. Preferential expression of SCN1A in GABAergic neurons improves survival and epileptic phenotype in a mouse model of Dravet syndrome

    Journal of Molecular Medicine, Vol. 101, Núm. 12, pp. 1587-1601

  5. Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial

    Cancer, Vol. 129, Núm. 12, pp. 1846-1855

  6. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

    Genome Medicine, Vol. 15, Núm. 1

  7. The Lucerne Toolbox 2 to optimise axillary management for early breast cancer: a multidisciplinary expert consensus

    eClinicalMedicine, Vol. 61